Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 12/20 | 0.72 |
| ▸ | PAK4 | O96013 | 3/20 | 0.72 |
| ▸ | SIK1 | P57059 | 1/20 | 0.68 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.68 |
| ▸ | MET | P08581 | 5/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15799616 | 0.89 | SIK1 (0.80) | PAK1PAK4SIK1SIK3MET | |
| SCHEMBL19860022 | 0.89 | SIK1 (0.79) | PAK1PAK4SIK1SIK3MET | |
| SCHEMBL15805359 | 0.81 | SIK1 (1.00) | PAK1PAK4SIK1SIK3MET | |
| Hydrochloric Acid SCHEMBL15562407 | 0.81 | MET (0.67) | PAK1PAK4SIK1SIK3MET | |
| SCHEMBL15799707 | 0.81 | PAK1 (0.66) | PAK1PAK4SIK1SIK3MET | |
| Hydrochloric Acid SCHEMBL15562445 | 0.80 | ALK (0.74) | PAK1PAK4SIK1SIK3MET | |
| SCHEMBL15805268 | 0.80 | PAK1 (0.84) | PAK1PAK4MET | |
| SCHEMBL19860027 | 0.79 | SIK1 (0.65) | PAK1PAK4SIK1SIK3MET | |
| SCHEMBL15562497 | 0.79 | PAK1 (0.68) | PAK1PAK4SIK1SIK3MET | |
| Hydrochloric Acid SCHEMBL15562705 | 0.78 | ALK (0.71) | PAK1PAK4SIK1SIK3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |